Is Sermorelin Legal in Arizona? How to Access It Legally

What Is Sermorelin and Why Does Its Legal Status Matter?

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates pulsatile release of endogenous growth hormone rather than supplying exogenous GH directly. [1]

That mechanism matters legally. Exogenous human growth hormone (hGH) falls under 21 U.S.C. § 333(e), which restricts its use to a narrow list of FDA-approved indications and prohibits off-label distribution by pharmacies. Sermorelin is not hGH. It is a secretagogue, so it does not carry the same statutory restrictions. [2]

How Sermorelin Differs From Synthetic HGH

Prescribers and patients sometimes conflate sermorelin with recombinant hGH products such as somatropin. The distinction is more than semantic.

Somatropin carries an explicit statutory barrier: under the Anabolic Steroid Control Act extensions and the HGH-specific provisions of the Food, Drug, and Cosmetic Act, dispensing hGH for anti-aging or bodybuilding is a federal felony. [2] Sermorelin carries no equivalent provision. A 2019 review in the Journal of Clinical Endocrinology and Metabolism noted that GHRH analogues "restore more physiologic GH pulsatility than exogenous GH replacement" in adults with age-related GH decline, which is part of why clinicians prefer secretagogues. [3]

Original Approval and the 2008 Discontinuation

The FDA approved sermorelin acetate (brand name Geref Diagnostic) in 1997 for diagnostic evaluation of pituitary GH secretion in children. [4] Serono discontinued the product in 2008 for commercial, not safety, reasons. Discontinuation does not equate to withdrawal for safety reasons, and that distinction is legally meaningful: compounding pharmacies may compound drugs whose brand versions were discontinued for commercial reasons as long as the compound does not appear on FDA's "Demonstrably Difficult to Compound" or "Category 1 Bulk" lists. As of the date of this article's last review, sermorelin does not appear on either FDA list. [5]

Federal Compounding Law: 503A vs. 503B

Understanding whether your pharmacy is operating under 503A or 503B rules affects what you receive, how much oversight applies, and whether the pharmacy can ship across state lines.

503A: Traditional Compounding for Individual Patients

Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies. To compound lawfully under 503A, a pharmacy must:

• Compound only in response to a valid patient-specific prescription
• Not compound drugs that appear on the FDA "Category 1" bulk list
• Comply with USP <795> and USP <797> standards for sterile preparations
• Be licensed by the state pharmacy board where they operate [6]

Sermorelin is a sterile injectable, so USP <797> sterility standards apply. These include environmental monitoring, beyond-use dating, and container closure integrity testing. A 503A pharmacy in Arizona or shipping into Arizona must meet all of these requirements.

503B: Outsourcing Facilities

Section 503B facilities register with the FDA directly and can produce larger batch quantities without a patient-specific prescription. They must comply with current Good Manufacturing Practice (cGMP) standards, which are more stringent than 503A requirements. [7] Sermorelin compounds from a 503B facility are generally considered higher-assurance products because of mandatory FDA inspections.

The FDA's guidance document "Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved BLA" does not classify sermorelin as a biological product subject to BLA requirements, so 503B facilities may compound it under standard small-molecule compounding rules. [7]

Arizona State Law: What the AZSBP Requires

Arizona does not have a sermorelin-specific statute. Legal access flows through the general framework of the Arizona State Board of Pharmacy (AZSBP) and the Arizona Medical Practice Act (A.R.S. Title 32, Chapter 13).

Arizona Pharmacy Board Rules for Sterile Compounding

The AZSBP requires all sterile compounding to comply with USP <797>. Arizona-licensed compounding pharmacies must hold a "Sterile Compounding" endorsement on their pharmacy permit. [8] A prescription for sermorelin filled by a pharmacy lacking this endorsement would not meet state standards.

Out-of-state pharmacies shipping sermorelin into Arizona must either hold a non-resident pharmacy permit issued by the AZSBP or operate as an FDA-registered 503B outsourcing facility. [8] Patients receiving sermorelin via mail should verify one of these two statuses before accepting a shipment.

The Arizona Medical Practice Act and Prescriber Requirements

Under A.R.S. § 32-1401, a licensed physician practicing in Arizona may prescribe any non-scheduled Rx drug for any condition where a reasonable clinical basis exists. Sermorelin is not scheduled, so no DEA authorization is required beyond a standard DEA registration number (which Arizona prescribers hold for general controlled-substance prescribing). [9]

Nurse practitioners and physician assistants in Arizona have full prescriptive authority for non-controlled substances without physician collaboration requirements, following Arizona's 2019 NP full-practice authority legislation. [10] This means a telehealth NP licensed in Arizona can legally prescribe sermorelin after a proper evaluation.

Telehealth Prescribing in Arizona

Arizona enacted H.B. 2454 in 2021 to formalize telehealth prescribing standards. A prescriber may issue an Rx for sermorelin via telehealth if the encounter includes a clinical evaluation, a review of relevant labs (IGF-1, metabolic panel), and documentation of medical necessity. [11] A prescription issued without any clinical evaluation, lab review, or documented rationale would not meet Arizona's standard of care, regardless of the drug's legal status.

Clinical Basis for Prescribing Sermorelin in Arizona

Arizona physicians prescribe sermorelin primarily for adult growth hormone deficiency (AGHD) and age-related decline in GH secretion. The Endocrine Society's 2011 clinical practice guideline defines AGHD diagnosis as requiring either a peak GH response <3 mcg/L on a glucagon stimulation test or <5 mcg/L on an insulin tolerance test, in the right clinical context. [12]

IGF-1 as a Screening Tool

Serum IGF-1 is the standard outpatient screening test for GH axis disorders. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism found that IGF-1 below the age-adjusted reference range carries a sensitivity of approximately 74% for diagnosing AGHD in adults with three or more pituitary deficiencies. [13] Most Arizona telemedicine providers use IGF-1 as the entry-point lab before initiating sermorelin.

Evidence for Sermorelin's Efficacy

A 6-month randomized trial by Walker et al. (N=89) showed that sermorelin acetate 0.03 mg/kg/day subcutaneously raised mean IGF-1 levels from 131 ng/mL to 249 ng/mL, a 90% increase, compared with a 6% change on placebo (P<0.001). [14] Lean body mass increased by 1.6 kg in the sermorelin group versus 0.1 kg on placebo over the same period.

A practical prescribing framework used at HealthRX starts with a baseline IGF-1 and fasting glucose, initiates sermorelin at 0.2 mg subcutaneously at bedtime, rechecks IGF-1 at 8 weeks, and titrates to 0.3 mg if IGF-1 remains below the midpoint of the age-adjusted reference range. Fasting glucose is rechecked at 12 weeks because sermorelin-driven GH elevation may cause transient insulin resistance. This approach aligns with the Endocrine Society's recommendation that "GH therapy should be titrated based on clinical response, serum IGF-1 levels, and tolerability." [12]

Side Effects Relevant to Prescribing Decisions

Common side effects include injection-site erythema (reported in 17% of participants in clinical trials), transient fluid retention, and headache. [4] These are generally dose-dependent and resolve with dose reduction. Sermorelin is contraindicated in active malignancy because GH axis stimulation may promote tumor growth, a consideration Arizona prescribers must document in the chart.

How to Get Sermorelin in Arizona: Step-by-Step

Getting a legal sermorelin prescription in Arizona follows the same steps as any Rx drug, with a few peptide-specific checkpoints.

Step 1: Choose a Licensed Prescriber

Select an Arizona-licensed MD, DO, NP, or PA. In-person visits work, but telehealth is fully legal. Confirm the provider has a valid Arizona license on the AZSBP license lookup or the Arizona Medical Board's public roster.

Step 2: Complete Lab Work

Request an IGF-1 (insulin-like growth factor 1), comprehensive metabolic panel, lipid panel, and fasting insulin before your appointment. Most labs (LabCorp, Quest) can process these without a primary-care referral if ordered directly by the telehealth provider.

Step 3: Clinical Evaluation

The prescriber reviews your symptoms (fatigue, reduced muscle mass, increased adiposity, poor sleep), your labs, and your medical history. They must document a clinical rationale for the prescription. This step cannot be skipped under Arizona's telehealth prescribing standards. [11]

Step 4: Prescription to a Licensed Compounding Pharmacy

The Rx should go to an AZSBP-endorsed sterile compounding pharmacy or an FDA-registered 503B outsourcing facility. Ask the pharmacy for their AZSBP permit number and, if applicable, their FDA registration number. You can verify 503B registration at the FDA's outsourcing facility list. [7]

Step 5: Follow-Up Labs at 8 Weeks

Arizona standard of care for peptide therapy includes a follow-up IGF-1 and fasting glucose at 8 weeks. Document the response. If IGF-1 has not risen to the midpoint of the age-adjusted reference range, the prescriber may titrate the dose upward, typically to 0.3 mg nightly.

What Would Make Sermorelin Illegal in Arizona?

Sermorelin access becomes legally problematic under specific circumstances, and patients should understand these clearly.

No Valid Prescription

Purchasing sermorelin without a prescription, including from overseas internet pharmacies or research-chemical vendors who sell it as a "research peptide," violates both federal law (21 U.S.C. § 353) and Arizona law (A.R.S. § 32-1968). [9] "Research peptide" sermorelin sold without a prescription is not FDA-reviewed for sterility, potency, or purity and carries genuine clinical risk.

Pharmacy Without Sterile Compounding Authorization

Receiving sermorelin from a 503A pharmacy that lacks a sterile compounding endorsement violates USP <797> requirements adopted by Arizona. [8] The product may be unsafe even if the transaction looks routine.

If FDA Places Sermorelin on the Category 1 Bulk List

The FDA periodically updates its bulk drug substances lists. If sermorelin is added to the "Category 1" list in a future rulemaking, 503A compounding would be prohibited. The FDA's current list, updated through 2024, does not include sermorelin. [5] Prescribers and patients should monitor FDA rulemaking at FDA.gov for future changes.

Frequently Asked Questions